Shopping Cart 0
Cart Subtotal
USD 0

Tyrosine-Protein-Kinase-CSK-(C-Src-Kinase-or-Protein-Tyrosine-Kinase-CYL-or-CSK-or-EC-2.7.10.2)-Pipeline-Review-H2-2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 10500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)-Pipeline Review, H2 2017

Summary

According to the recently published report 'Tyrosine Protein Kinase CSK-Pipeline Review, H2 2017'; Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) pipeline Target constitutes close to 14 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes.

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)-Tyrosine-protein kinase CSK also known as C-terminal Src kinase is an enzyme that, in humans, is encoded by the CSK gene. It plays an important role in the regulation of cell growth, differentiation, migration and immune response. It phosphorylates tyrosine residues located in the C-terminal tails of Src-family kinases (SFKs). To inhibit SFKs, CSK is recruited to the plasma membrane via binding to transmembrane proteins or adapter proteins located near the plasma membrane. It suppresses signaling by various surface receptors including T-cell receptor (TCR) and B-cell receptor (BCR).

The report 'Tyrosine Protein Kinase CSK-Pipeline Review, H2 2017' outlays comprehensive information on the Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 5 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Dermatology, Immunology and Infectious Disease which include indications Breast Cancer, Gastric Cancer, High-Grade Glioma, Melanoma, Ovarian Cancer, Solid Tumor, Actinic (Solar) Keratosis, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Arrhythmias, Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Colorectal Cancer, Epstein-Barr Virus (HHV-4) Infections, Esophageal Cancer, Fallopian Tube Cancer, Gallbladder Cancer, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Glioma, Hematological Tumor, Hepatocellular Carcinoma, Lymphoma, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Mild Cognitive Impairment, Myocardial Infarction, Nasopharyngeal Cancer, Non-Small Cell Lung Cancer, Osteosarcoma, Peritoneal Cancer, Prostate Cancer, Psoriasis, Renal Cell Carcinoma, Skin Cancer, Small-Cell Lung Cancer, Stroke, Thrombosis and Thyroid Cancer.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)

The report reviews Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)-Overview

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)-Companies Involved in Therapeutics Development

Advenchen Laboratories LLC

Athenex Inc

Basilea Pharmaceutica Ltd

Pfizer Inc

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)-Drug Profiles

apatinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bosutinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCT-196969-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCT-241161-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eCF-506-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KX-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KX-02-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PP-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit c-Src Tyrosine Kinase for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit C Src Kinase for Colon Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Src Kinase for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit CSK for Stroke and Thrombosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit Src Tyrosine Kinase for Prostate Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UM-164-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)-Dormant Products

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)-Discontinued Products

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)-Product Development Milestones

Featured News & Press Releases

May 24, 2017: Athenex and Its Partner, Guangzhou Xiangxue Pharmaceutical, Announced Chinese FDA IND Approval to Begin Clinical Trials of KX-02 Tablet for Glioblastoma

May 16, 2017: LSK Biopharma Announces Starting of Site Initiation Visits in the U.S. for its Phase 3 Gastric Cancer Trial Studying Apatinib

May 08, 2017: Lsk Biopharma Announces Approval to Initiate a Phase 2 Clinical Trial in Colorectal Cancer in South Korea

Mar 13, 2017: LSK BioPharma Announces Enrollment of First Patient in Phase 3 Apatinib Trial in Gastric Cancer

Mar 01, 2017: LSK BioPharmas Apatinib Receives Orphan Drug Designation in the European Union

Jan 06, 2017: Lsk Biopharma Receives Approval to Initiate Phase 3 from Korea's, Expects First-Patient-Enrolled in Global Phase 3 Shortly

Dec 05, 2016: Pfizer and Avillion Announce Positive Top-Line Results for Phase 3 BFORE Study of BOSULIF for First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Oct 18, 2016: Athenex announces Xiangxue Pharmaceuticals, its KX-02 development partner in China, has achieved a regulatory milestone in that territory

Sep 21, 2016: Lsk Biopharma Receives Advice from CHMP Supporting its Plan to Enroll European Patients in Global Phase 3

Sep 21, 2016: LSKB to Report Phase 2 Apatinib Clinical Data at 2016 ESMO Congress

Aug 24, 2016: NICE approves new cancer drug bosutinib for routine NHS use

Jul 26, 2016: LSK BioPharma Announces Successful Outcome from End-of-Phase 2 meeting with FDA

Jul 07, 2016: NICE approves first drug from old Cancer Drugs Fund

Jun 08, 2016: New compound shows potential for triple-negative breast cancer

May 23, 2016: Breast cancer drug discovery offers hope of new treatments

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Advenchen Laboratories LLC, H2 2017

Pipeline by Athenex Inc, H2 2017

Pipeline by Basilea Pharmaceutica Ltd, H2 2017

Pipeline by Pfizer Inc, H2 2017

Dormant Projects, H2 2017

Discontinued Products, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) Therapeutic Products under Development, Key Players in Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) Therapeutics, Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) Pipeline Overview, Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) Pipeline, Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) Pipeline Assessment


Companies

Advenchen Laboratories LLC

Athenex Inc

Basilea Pharmaceutica Ltd

Pfizer Inc

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)-Pipeline Review, H2 2017

Summary

According to the recently published report 'Tyrosine Protein Kinase CSK-Pipeline Review, H2 2017'; Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) pipeline Target constitutes close to 14 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes.

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)-Tyrosine-protein kinase CSK also known as C-terminal Src kinase is an enzyme that, in humans, is encoded by the CSK gene. It plays an important role in the regulation of cell growth, differentiation, migration and immune response. It phosphorylates tyrosine residues located in the C-terminal tails of Src-family kinases (SFKs). To inhibit SFKs, CSK is recruited to the plasma membrane via binding to transmembrane proteins or adapter proteins located near the plasma membrane. It suppresses signaling by various surface receptors including T-cell receptor (TCR) and B-cell receptor (BCR).

The report 'Tyrosine Protein Kinase CSK-Pipeline Review, H2 2017' outlays comprehensive information on the Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 5 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Dermatology, Immunology and Infectious Disease which include indications Breast Cancer, Gastric Cancer, High-Grade Glioma, Melanoma, Ovarian Cancer, Solid Tumor, Actinic (Solar) Keratosis, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Arrhythmias, Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Colorectal Cancer, Epstein-Barr Virus (HHV-4) Infections, Esophageal Cancer, Fallopian Tube Cancer, Gallbladder Cancer, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Glioma, Hematological Tumor, Hepatocellular Carcinoma, Lymphoma, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Mild Cognitive Impairment, Myocardial Infarction, Nasopharyngeal Cancer, Non-Small Cell Lung Cancer, Osteosarcoma, Peritoneal Cancer, Prostate Cancer, Psoriasis, Renal Cell Carcinoma, Skin Cancer, Small-Cell Lung Cancer, Stroke, Thrombosis and Thyroid Cancer.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)

The report reviews Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)-Overview

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)-Companies Involved in Therapeutics Development

Advenchen Laboratories LLC

Athenex Inc

Basilea Pharmaceutica Ltd

Pfizer Inc

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)-Drug Profiles

apatinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bosutinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCT-196969-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCT-241161-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eCF-506-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KX-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KX-02-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PP-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit c-Src Tyrosine Kinase for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit C Src Kinase for Colon Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Src Kinase for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit CSK for Stroke and Thrombosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit Src Tyrosine Kinase for Prostate Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UM-164-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)-Dormant Products

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)-Discontinued Products

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)-Product Development Milestones

Featured News & Press Releases

May 24, 2017: Athenex and Its Partner, Guangzhou Xiangxue Pharmaceutical, Announced Chinese FDA IND Approval to Begin Clinical Trials of KX-02 Tablet for Glioblastoma

May 16, 2017: LSK Biopharma Announces Starting of Site Initiation Visits in the U.S. for its Phase 3 Gastric Cancer Trial Studying Apatinib

May 08, 2017: Lsk Biopharma Announces Approval to Initiate a Phase 2 Clinical Trial in Colorectal Cancer in South Korea

Mar 13, 2017: LSK BioPharma Announces Enrollment of First Patient in Phase 3 Apatinib Trial in Gastric Cancer

Mar 01, 2017: LSK BioPharmas Apatinib Receives Orphan Drug Designation in the European Union

Jan 06, 2017: Lsk Biopharma Receives Approval to Initiate Phase 3 from Korea's, Expects First-Patient-Enrolled in Global Phase 3 Shortly

Dec 05, 2016: Pfizer and Avillion Announce Positive Top-Line Results for Phase 3 BFORE Study of BOSULIF for First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Oct 18, 2016: Athenex announces Xiangxue Pharmaceuticals, its KX-02 development partner in China, has achieved a regulatory milestone in that territory

Sep 21, 2016: Lsk Biopharma Receives Advice from CHMP Supporting its Plan to Enroll European Patients in Global Phase 3

Sep 21, 2016: LSKB to Report Phase 2 Apatinib Clinical Data at 2016 ESMO Congress

Aug 24, 2016: NICE approves new cancer drug bosutinib for routine NHS use

Jul 26, 2016: LSK BioPharma Announces Successful Outcome from End-of-Phase 2 meeting with FDA

Jul 07, 2016: NICE approves first drug from old Cancer Drugs Fund

Jun 08, 2016: New compound shows potential for triple-negative breast cancer

May 23, 2016: Breast cancer drug discovery offers hope of new treatments

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Advenchen Laboratories LLC, H2 2017

Pipeline by Athenex Inc, H2 2017

Pipeline by Basilea Pharmaceutica Ltd, H2 2017

Pipeline by Pfizer Inc, H2 2017

Dormant Projects, H2 2017

Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) Therapeutic Products under Development, Key Players in Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) Therapeutics, Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) Pipeline Overview, Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) Pipeline, Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) Pipeline Assessment


Companies

Advenchen Laboratories LLC

Athenex Inc

Basilea Pharmaceutica Ltd

Pfizer Inc